Indian Civil Society letter on TB Declaration negotiations -UN High Level Meeting


Mr. Narendra Modi, Prime Minister of India

Mr. J. P. Nadda, Health Minister

Ms. Sushma Swaraj, Foreign Minister

Mr. Suresh Prabhu, Commerce Minister

Date: 31st July 2018

Sub: Asking India to support TRIPS flexibilities in UN High Level Meeting on TB

Dear Mr. Modi, Mr. Nadda, Ms. Swaraj and Mr. Prabhu,

We, the undersigned, would like to draw your attention to the ongoing negotiations on the Political Declaration on the Fight against Tuberculosis in New York. It is well recognized that tuberculosis, including its drug-resistant forms, is a critical challenge and the leading infectious disease cause of death, the most common form of antimicrobial resistance globally. Continue reading

Posted in Access to Medecines, Delinkage, R&D, TRIPS, TRIPS flexibilities, Tuberculosis (TB), Uncategorized | Leave a comment

Study published in BMJ shows that expenditure on medicines constitutes the single largest component of the total Out of Pocket payments by households

Thirty-eight million people slipped into poverty owing to expenses on medicines in year 2011-12. Just for perspective, poverty line in rural India is USD 11.82 a month, and for urban India it is calculated at 14.48 a month.

Click here for the study.

Posted in Uncategorized | Leave a comment

Here’s the short note on UNHLM on TB and US pressurising to dilute TRIPS flexibilities

The United Nations is going to hold a High Level Meeting on TB in New York in September. The member countries of UN will sign on a declaration will set the direction in which work on TB, globally, will move. The Draft Political Declaration on Fight against Tuberculosis is being negotiated by member countries this week. Continue reading

Posted in TRIPS, TRIPS flexibilities, Tuberculosis (TB), US Pressure | Leave a comment

Quick Takeaways from #AffordableMedsNow Conference

18th July 2018, New Delhi

Source: Pens and Needles

access to medicines

Protestors march around a monument while holding signs.

🔊 Listen to Post

Last week, Public Citizen hosted the “Affordable Medicines Now” conference at Georgetown Law in Washington, DC. The event, organized by Public Citizen’s Justin Mendoza (@JustinDMendoza), featured three days of speakers and panels in which activists, legislators, and experts addressed topics related to drug pricing. Here are seven themes that emerged from the conference:

1. There is no room for Pharma in patient advocacy.

Several speakers stressed that patient advocacy with industry ties is NOT patient advocacy. For this reason, Gregg Gonsalves (@gregggonsalves) says, advocates have a duty to “call out” friends who work for organizations that accept funding from Pharma.

This perspective was reinforced by Marina Tsaplina (@thebetesorg), Founder and CEO of THE BETES Organization, who described her own conflicts of interest while the recipient Continue reading

Posted in Access to Medecines | Leave a comment

People living with hepatitis C and HIV challenge evergreening patents on lifesaving hepatitis C drugs in India

New Delhi, 10 July 2018: Delhi Network of Positive People (DNP+) has filed today two patent oppositions before the Indian patent office, challenging additional patent claims by US pharmaceutical corporation-Gilead Sciences for the hepatitis C medicines sofosbuvir and velpatasvir. These oppositions challenge Gilead’s patent applications for the tablet formulation of the fixed-dose combination of sofosbuvir/velpatasvir and the polymorph form of velpatasvir.

Continue reading

Posted in Drug prices, Hepatitis C, Indian Patent Law, Patent, Patent Opposition, Sec 3 (d) | Tagged , | Leave a comment

The grounds for opposing patent applications for velpatasvir

Source: MSF | July 09, 2018

Gilead Sciences has applied for multiple patents on oral hepatitis C medicines – sofosbuvir and velpatasvir in India: not only limiting itself to basic patents but also staking claims on a number of additional patents for routine improvements and derivatives. This brief provides technical information based Continue reading

Posted in Patent linkage, Patent Opposition, Patent Term Extension, Patents | Leave a comment

Intellectual Property rules stand amended

Source: The Hindu | July 02, 2018

Some powers with Customs revoked

The Union Ministry of Finance has amended Intellectual Property rules to revoke the power vested with Customs authorities to seize imported products based on complaints of patent infringement.

On June 22, the Ministry made two amendments to the Intellectual Property Rights (Imported Goods) Enforcement Rules, 2007. Firstly, the Intellectual Property Rights (Imported Goods) Enforcement Amendment Rules, 2018, omits all reference to the Patents Act, 1970. Continue reading

Posted in IPR Enforcement, IPR policy, Patent infringement | Leave a comment